TMO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

11.95B

+4.89%

6.450

+5.74%

11.03B

+6.41%

5.595

+8.64%

11.48B

+5.71%

5.873

+9.57%

Estimates Revision

The market is revising Upward the revenue expectations for Thermo Fisher Scientific Inc. (TMO) for FY2025, with the revenue forecasts being adjusted by 0.85% over the past three months. During the same period, the stock price has changed by 20.63%.

Revenue Estimates for FY2025

Revise Upward

+0.85%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1%

In Past 3 Month

Stock Price

Go Up

+20.63%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

3 Hold

0 Sell

Strong Buy

Current: 570.160

Low

561.00

Averages

615.44

High

675.00

Current: 570.160

Low

561.00

Averages

615.44

High

675.00

BofA

Buy

maintain

$650 -> $700

2025-12-15

New

Reason

BofA

Price Target

$650 -> $700

2025-12-15

New

maintain

Buy

Reason

BofA raised the firm's price target on Thermo Fisher to $700 from $650 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Wells Fargo

NULL -> Overweight

maintain

$635 -> $675

2025-12-15

New

Reason

Wells Fargo

Price Target

$635 -> $675

2025-12-15

New

maintain

NULL -> Overweight

Reason

Wells Fargo raised the firm's price target on Thermo Fisher to $675 from $635 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Citi

Patrick Donnelly

Neutral -> Buy

upgrade

$580 -> $660

2025-12-11

Reason

Citi

Patrick Donnelly

Price Target

$580 -> $660

2025-12-11

upgrade

Neutral -> Buy

Reason

Citi analyst Patrick Donnelly upgraded Thermo Fisher to Buy from Neutral with a price target of $660, up from $580. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. Citi sees Thermo Fisher benefitting from increased pharma spending and onshoring tailwinds.

Goldman Sachs

Evie Koslosky

initiated

$685

2025-12-09

Reason

Goldman Sachs

Evie Koslosky

Price Target

$685

2025-12-09

initiated

Reason

Goldman Sachs analyst Evie Koslosky initiated coverage of Thermo Fisher with a Buy rating and $685 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.

KeyBanc

Sector Weight -> Overweight

upgrade

$750

2025-12-08

Reason

KeyBanc

Price Target

$750

2025-12-08

upgrade

Sector Weight -> Overweight

Reason

KeyBanc last night upgraded Thermo Fisher to Overweight from Sector Weight with a $750 price target. The firm cites improving macro conditions and the company's "strong execution" for the upgrade. Bopharma spend is normalizing and key areas like bio-production and research and safety are seeing outsized growth, the analyst tells investors in a research note. KeyBanc is also positive on Thermo's precise acquisition strategy, which it believes should drive accelerating growth.

KeyBanc

Paul Knight

Sector Weight -> Overweight

upgrade

$750

2025-12-07

Reason

KeyBanc

Paul Knight

Price Target

$750

2025-12-07

upgrade

Sector Weight -> Overweight

Reason

KeyBanc analyst Paul Knight upgraded Thermo Fisher to Overweight from Sector Weight with a $750 price target.

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO.N) is 23.67, compared to its 5-year average forward P/E of 24.11. For a more detailed relative valuation and DCF analysis to assess Thermo Fisher Scientific Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

24.11

Current PE

23.67

Overvalued PE

26.98

Undervalued PE

21.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

20.73

Current EV/EBITDA

20.93

Overvalued EV/EBITDA

22.78

Undervalued EV/EBITDA

18.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.94

Current PS

4.65

Overvalued PS

5.56

Undervalued PS

4.32

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 226.18% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 226.18% over the last month.

Sold

Bought

TMO News & Events

Events Timeline

No data

News

8.5

12-15Newsfilter

PinnedOlivePoint Acquires Class A Office in RTP, Enhancing Yield Potential

3.5

09:15 AMYahoo Finance

North America Set to Experience Leading Growth in Microplastic Analysis Market with 8.5% CAGR

6.0

12-15CNBC

Monday's Top Analyst Recommendations: Nvidia, Tesla, Apple, Viking, Hershey, Marriott, Dollar General, and More

People Also Watch

Frequently Asked Questions

What is Thermo Fisher Scientific Inc (TMO) stock price today?

The current price of TMO is 570.16 USD — it has decreased -1 % in the last trading day.

What is Thermo Fisher Scientific Inc (TMO)'s business?

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.

What is the price predicton of TMO Stock?

What is Thermo Fisher Scientific Inc (TMO)'s revenue for the last quarter?

Thermo Fisher Scientific Inc revenue for the last quarter amounts to 11.12B USD, increased 4.94 % YoY.

What is Thermo Fisher Scientific Inc (TMO)'s earnings per share (EPS) for the last quarter?

Thermo Fisher Scientific Inc. EPS for the last quarter amounts to 4.28 USD, increased 0.94 % YoY.

What changes have occurred in the market's expectations for Thermo Fisher Scientific Inc (TMO)'s fundamentals?

How many employees does Thermo Fisher Scientific Inc (TMO). have?

Thermo Fisher Scientific Inc (TMO) has 125000 emplpoyees as of December 17 2025.

What is Thermo Fisher Scientific Inc (TMO) market cap?

Today TMO has the market capitalization of 214.21B USD.